LigaChem Biosciences Amends Capital Increase Terms
리가켐바이오
141080
Signal Score
Historical Avg Return (5d)
+0.00%
Data Coverage
100%n=2571
Risk-adjusted indicator based on 2571 historical DART filings. For informational purposes only — not investment advice.
Financial Impact
NEGATIVE
Key Numbers
- • New Shares Issued: 2,718,284 Shares (previously 2,210,313 Shares)
- • Conversion Price: 121,400 KRW/Share (previously 149,300 KRW/Share)
- • Funding for Operations: 329,999,677,600 KRW (previously 329,999,730,900 KRW)
- • Dilution Rate: 6.84% (previously 5.97%)
- • Issue Price: 121,400 KRW/Share (previously 149,300 KRW/Share)
AI Analysis Summary
LigaChem Biosciences Inc. has amended its paid-in capital increase, increasing the number of new shares to be issued from 2,210,313 to 2,718,284 and lowering the conversion price from 149,300 KRW/Share to 121,400 KRW/Share. The total operational funding remains largely similar at approximately 329.99 billion KRW. This adjustment results in a higher maximum potential dilution rate for existing shareholders, increasing from 5.97% to 6.84%. The lower conversion price and increased share count are generally negative for existing shareholders due to increased dilution.
How This Event Is Evaluated
Capital Raise Evaluation
Capital raise events are evaluated by estimating dilution pressure, funding purpose, pricing terms, and impact on existing shareholders.
AI is used to interpret disclosures and extract structured data.
Signal scores are generated using event-specific methodologies and quantitative models.
- Potential dilution rate
- Issuance or conversion price
- Funding purpose
- Shareholder value impact
Track Korean Market Signals — Free
Sign up free to access live disclosures, AI analysis, and event filters.
Public Beta · No credit card required
This content is for informational purposes only and does not constitute investment advice. Past signal patterns do not guarantee future results. All data is sourced from public DART filings.